Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613844 | 0.81 | ERN1 (0.46) | ERN1CTSAMRGPRX4PRMT5GRM2 | |
| SCHEMBL8615551 | 0.79 | ERN1 (0.49) | ERN1CTSAMRGPRX4PRMT5GRM2 | |
| SCHEMBL31086460 | 0.79 | PRMT5 (0.53) | PRMT5XDH | |
| SCHEMBL31391067 | 0.79 | ALDH1A1 (0.52) | AAK1KMOCDK2EGFR | |
| SCHEMBL29254767 | 0.79 | PRMT5 (0.53) | PRMT5XDH | |
| SCHEMBL2759526 | 0.79 | AAK1 (0.45) | AAK1KMOCCNT1CDK9 | |
| SCHEMBL8611382 | 0.79 | ALOX5AP (0.47) | ERN1CTSAMRGPRX4PRMT5GRM2 | |
| SCHEMBL8616633 | 0.79 | MRGPRX4 (0.48) | ERN1CTSAMRGPRX4PRMT5 | |
| SCHEMBL6638721 | 0.76 | FEN1 (0.48) | ERN1CTSAPRMT5 | |
| SCHEMBL20543912 | 0.76 | ERN1 (0.43) | ERN1CTSAMRGPRX4PRMT5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | ERN1 1533/4885CTSA 505/4885MRGPRX4 4370/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | ERN1 1982/4885CTSA 636/4885MRGPRX4 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.